Medeze Group Seen Benefiting in Shift From Biotech to Biopharma — Market Talk

About this update from Medeze Group Public Company Limited

Medeze Group is expected to gain from its new strategic growth engines, CGS International's Kasem Prunratanamala says in a research report. The stem cell services provider is expected to secure Thailand's good manufacturing practice certification and official cell banking accreditation in 2026, the analyst says. This, combined with its transformation from a biotech to a biopharma player, should be a key growth driver, says the brokerage, which forecasts the company's 2025-2028 EPS CAGR at 35.1%. This strategic shift should reinforce the company's market leadership and competitive advantage via a more comprehensive service offering. The brokerage initiates coverage of the stock with an add rating and a target price of 7.90 baht. Shares are 0.8% higher at 6.20 baht. ([email protected])

View stock analysis, news, and events for Medeze Group Public Company Limited